Pay in 4 interest-free payments of $6.29 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Common side effects (usually mild) Injection-related: Injection site redness or irritation Mild pain at injection site Temporary skin induration GH-related: Water retention (usually temporary) Mild headaches (especially initially) Increased hunger (less than GHRP-6) Tingling or numbness (rare, usually at high doses) Sleep-related: Vivid dreams (often reported, not necessarily unpleasant) Temporary sleep disturbance during adjustment Less common side effects At higher doses or prolonged use: Joint stiffness or mild carpal tunnel symptoms Flushing Dizziness Fatigue (paradoxically, sometimes) What Ipamorelin typically doesn't cause Unlike other GHRPs: No significant cortisol elevation No significant prolactin increase No intense hunger spikes No blood sugar disruption Managing side effects For water retention: Usually resolves within 2-4 weeks Reduce sodium intake Stay well-hydrated Consider reducing dose temporarily For headaches: Often occur during first week Ensure proper hydration Start with lower dose and titrate up Usually resolve with continued use For injection site reactions: Rotate injection sites Ensure proper injection technique Allow alcohol to dry before injecting Use fresh needles Contraindications Do not use Ipamorelin if you have: Active cancer or history of cancer Uncontrolled diabetes Severe cardiovascular disease Pregnancy or breastfeeding Known allergy to peptide components Use with caution if you have: Diabetes (monitor blood sugar closely) History of carpal tunnel syndrome Pituitary disorders Any condition affected by growth hormone For comprehensive safety information, see our peptide safety guide
States including Idaho and Tennessee have announced investigations into illegal dispensing by medical spas and other providers, while states such as California are looking to beef up their oversight
Glucagon-like Peptide-1 Agonists Market Size and Share Glucagon-like Peptide-1 Agonists Market Analysis by Mordor Intelligence The Glucagon-like Peptide-1 Agonists Market size is expected to grow from USD 46.18 billion in 2025 to USD 52.30 billion in 2026 and is forecast to reach USD 97.45 billion by 2031 at 13.26% CAGR over 2026-2031
It is no longer just a points-and-meetings program
Stay hydrated Hydration prevents gastrointestinal distress, headaches, and dizziness
To find out whether youre a candidate, take the intake assessment and a licensed provider will review your situation
